Immuron Ltd. Sponsored ADR
IMRN
Immuron Ltd. Sponsored ADR is the U.S.-listed depositary receipt for Immuron Limited, an Australian biopharmaceutical company focused on developing and commercializing oral polyclonal antibody products. Immuron’s current portfolio centers on products and programs designed for gastrointestinal and infectious disease applications, including Travelan, an over-the-counter product used to help reduce the risk of traveler’s diarrhea, and Protectyn, an immune supplement marketed for digestive health support. The company also maintains a research and development pipeline built around targeted antibody technologies and clinical-stage candidates for enteric and other gut-mediated conditions. Through its commercial products and clinical programs, Immuron participates in both consumer health and specialty biopharmaceutical markets, serving as a niche player in microbiome-linked and immune-focused therapies.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
A$7M
▲ +48.6% YoY
Net Income (TTM)
-A$5M
▲ +24.8% YoY
Op. Margin
-73.51%
▲ +32.9pp YoY
ROIC
-40.26%
▼ -15.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-A$6M
▼ -4.4% YoY
Op. Cash Flow (TTM)
-A$6M
▼ -4.4% YoY
Net Debt
-A$3M
Net Cash Position
Cash & Equiv.
A$3M
3Y CAGR: +142.8%
Continue Research
Peers
Biotechnology · Pick stocks to compare with IMRN
Immuron Ltd. Sponsored ADR (IMRN) in four numbers
Questions about Immuron Ltd. Sponsored ADR
Is Immuron Ltd. Sponsored ADR (IMRN) overvalued?
At $0.90, Immuron Ltd. Sponsored ADR's price is 89% below the $8.46 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Immuron Ltd. Sponsored ADR's fair value?
Intrinsiqq's calculator puts Immuron Ltd. Sponsored ADR's fair value at $8.46 a share. It grows revenue per share 30% a year for 5 years, applies an exit P/S of 4.4, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $6.34. Every input can be changed on the Intrinsic Value tab.
Is Immuron Ltd. Sponsored ADR a high-quality business?
Immuron Ltd. Sponsored ADR scores 40 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 6 checks computed from company filings. Its best check is revenue growth at 142.8%, and its weakest is return on capital at -40.3%. The Quality tab shows every check against its target.
Does Immuron Ltd. Sponsored ADR (IMRN) pay a dividend?
No. Immuron Ltd. Sponsored ADR (IMRN) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing IMRN
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.